Tocagen' experimental treatment did not prove effective in extending the life of brain cancer patients in a late-stage study, the company announced.

The California-based company said its lead product candidate Toca 511 & Toca FC also did not show meaningful superiority in secondary goals compared to standard of care treatment during the trial, Reuters reported.

The team plans to conduct an operational review of the business, engage with the FDA and European regulators to determine potential next steps,” the company said.

Toca 511 & Toca FC is a two-part cancer-selective immunotherapy that spares the blood cells from the common side effects associated with chemotherapy, as it is a targeted therapy.